The role of TMPRSS2 in COVID-19 is further confirmed by the fact that TMPRSS2 inhibitors approved for clinical use (such as camostat mesylate—a drug used in the treatment of chronic pancreatitis) can block SARS-CoV-2 virus infection (7). This evidence concerns the gene TMPRSS2 and COVID-19.